Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model

Overview of attention for article published in Blood Advances, March 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

So far, Altmetric has seen 17 X posts from 16 X users, with an upper bound of 132,179 followers.

Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. https://t.co/lD18UXLvtz

RT @BloodAdvances: BTZ triggers viral replication in the tumor microenvironment enhancing anticancer cytotoxic and immune modulatory signal…

BTZ triggers viral replication in the tumor microenvironment enhancing anticancer cytotoxic and immune modulatory signals. https://t.co/tRp3cCpXlb #Immunobiology #Immunotherapy #LymphoidNeoplasia https://t.co/BQPmRVegPh

RT @BloodAdvances: Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model #…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 13 additional X posts.